These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37634824)

  • 1. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport.
    Chu Y; Wong A; Chen H; Ji L; Qin C; Feng W; Stocks MJ; Gershkovich P
    Eur J Pharm Biopharm; 2023 Oct; 191():90-102. PubMed ID: 37634824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach.
    Qin C; Chu Y; Feng W; Fromont C; He S; Ali J; Lee JB; Zgair A; Berton M; Bettonte S; Liu R; Yang L; Monmaturapoj T; Medrano-Padial C; Ugalde AAR; Vetrugno D; Ee SY; Sheriston C; Wu Y; Stocks MJ; Fischer PM; Gershkovich P
    J Control Release; 2021 Jan; 329():1077-1089. PubMed ID: 33091528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
    Chu Y; Qin C; Feng W; Sheriston C; Jane Khor Y; Medrano-Padial C; Watson BE; Chan T; Ling B; Stocks MJ; Fischer PM; Gershkovich P
    Int J Pharm; 2021 Jun; 602():120621. PubMed ID: 33892057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
    Lee JB; Zgair A; Malec J; Kim TH; Kim MG; Ali J; Qin C; Feng W; Chiang M; Gao X; Voronin G; Garces AE; Lau CL; Chan TH; Hume A; McIntosh TM; Soukarieh F; Al-Hayali M; Cipolla E; Collins HM; Heery DM; Shin BS; Yoo SD; Kagan L; Stocks MJ; Bradshaw TD; Fischer PM; Gershkovich P
    J Control Release; 2018 Sep; 286():10-19. PubMed ID: 30016732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
    Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
    J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid.
    Han S; Quach T; Hu L; Lim SF; Zheng D; Leong NJ; Sharma G; Bonner D; Simpson JS; Trevaskis NL; Porter CJH
    Mol Pharm; 2023 May; 20(5):2675-2685. PubMed ID: 36996486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine.
    Xie Y; Lu Z; Styles IK; Reddiar SB; Phillips ARJ; Windsor JA; Porter CJH; Han S; Trevaskis NL
    J Pharm Sci; 2024 Aug; 113(8):2342-2351. PubMed ID: 38582284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors.
    Tian CT; Guo JJ; Miao YF; Wang HL; Ye Q; Guo CL; Zhang MY; He ZG; Sun J
    Eur J Pharm Biopharm; 2022 Jul; 176():122-132. PubMed ID: 35643367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.
    Elz AS; Trevaskis NL; Porter CJH; Bowen JM; Prestidge CA
    J Control Release; 2022 Jan; 341():676-701. PubMed ID: 34896450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.
    Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S
    Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
    Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
    Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug.
    Han S; Hu L; Quach T; Simpson JS; Trevaskis NL; Porter CJH
    J Pharm Sci; 2016 Feb; 105(2):786-796. PubMed ID: 26540595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle.
    Jewell A; Brookes A; Feng W; Ashford M; Gellert P; Butler J; Fischer PM; Scurr DJ; Stocks MJ; Gershkovich P
    Eur J Pharm Biopharm; 2022 May; 174():29-34. PubMed ID: 35364254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations.
    Khuroo T; Dharani S; Mohamed EM; Immadi S; Wu Z; Khan MA; Lu D; Nehete P; Rahman Z
    Int J Pharm; 2021 Sep; 607():120889. PubMed ID: 34271151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of lamivudine into lymph node HIV reservoir.
    Wong A; Chu Y; Chen H; Feng W; Ji L; Qin C; Stocks MJ; Marlow M; Gershkovich P
    Int J Pharm; 2023 Dec; 648():123574. PubMed ID: 37935311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery.
    Khuroo T; Mohamed EM; Dharani S; Immadi S; Nutan MTH; Lu D; Ali HI; Khan MA; Rahman Z
    J Pharm Sci; 2022 Aug; 111(8):2312-2321. PubMed ID: 35296412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs.
    Han S; Hu L; Gracia ; Quach T; Simpson JS; Edwards GA; Trevaskis NL; Porter CJ
    Mol Pharm; 2016 Oct; 13(10):3351-3361. PubMed ID: 27608166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.